SYMYOO was selected as CRO for iTARGET-Elderly Study, a large-scale registry-based randomized controlled trial (RRCT) led by the Korean Diabetes Association (KDA).

This study will compare and evaluate moderate-intensity statin therapy with an individualized LDL-C target-based therapy for the primary prevention effects of cardiovascular events in elderly patients with type 2 diabetes.

The large-scale study plans to enroll more than 2,000 participants across approximately 40 medical institutions in South Korea.

We, SYMYOO, are fully committed to ensuring the successful execution of the study with the highest level of expertise, contributing to the advancement of personalized treatment strategies for elderly patients with diabetes.